Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Cytochrome P450 3A4 (CYP3A4) is a crucial drug-metabolizing enzyme found in major organs.
• CYP3A4 activity is implicated in the progression of cancers, including lung cancer.
• Targeting CYP3A4 can optimize drug selection and prevent adverse drug reactions in cancer therapy.

Purpose of the Study:

• To investigate the binding interactions between chemotherapeutic drugs and human CYP3A4.
• To evaluate the binding affinities of various chemotherapy agents, individually and in combination, to CYP3A4.
• To identify key residues involved in drug binding for potential therapeutic targeting.

Main Methods:

• Molecular docking simulations using Schrödinger suite 2014 with Induced Fit Docking.
• Docking of gemcitabine, cisplatin, carboplatin, docetaxel, and paclitaxel to human CYP3A4.
• Evaluation of drug-binding affinities using Prime/MMGBSA and analysis of combination therapies.

Main Results:

• Gemcitabine exhibited the highest binding affinity to CYP3A4, followed by carboplatin and cisplatin.
• Docetaxel and paclitaxel did not demonstrate binding to the CYP3A4*1B variant.
• The combination of gemcitabine and carboplatin showed the highest binding affinity, suggesting enhanced efficacy.

Conclusions:

• Gemcitabine demonstrates significant binding affinity to CYP3A4, indicating its potential as a therapeutic agent in non-small cell lung cancer (NSCLC).
• The combination of gemcitabine and carboplatin may offer superior efficacy against CYP3A4 in NSCLC patients.
• Residue Arginine 105 (Arg 105) was identified as a key site for drug binding to CYP3A4, presenting a potential target for future therapies.